chemokines and contribute to continued cell death and a persistent inflammatory microenvironment within the injured spinal cord. 1, 2 In contrast, alternatively activated macrophages (M2) release anti-inflammatory cytokines and facilitate tissue repair. 2 Increasingly, clinicians and researcher are testing the therapeutic potential of drugs that polarize macrophage activation toward reparative phenotypes in a variety of CNS disorders.
Macrolide antibiotics are a class of natural products consisting of a highly substituted macrocyclic 14-, 15-, or 16-membered lactone ring. Azithromycin (AZM) is a 15-membered, second generation, synthetic derivative of erythromycin with improved pharmacokinetic properties and a broad antimicrobial spectrum. 3 Azithromycin is well tolerated and commonly prescribed. Moreover, AZM becomes highly concentrated in macrophages and other phagocytes. 4, 5 Across a variety of inflammatory conditions, AZM attenuates proinflammatory cytokine production by macrophages and other immune cells. 6 Azithromycin and other macrolide antibiotics are now being tested as immunomodulatory agents for CNS disorders.
Specifically, we and others observed immunomodulatory effects and improved recovery with AZM treatment in spinal cord injury, stroke, and retinal ischemia/reperfusion injury. [7] [8] [9] [10] [11] [12] The neuroprotective properties of AZM in these models are associated with direct effects on macrophages. [7] [8] [9] We have shown that in vitro application of AZM to proinflammatory M1 bone marrow-derived macrophages (BMDMs) dampens the release of proinflammatory cytokines, increases M2-associated anti-inflammatory cytokines, and reduces the neurotoxicity of M1 macrophage-conditioned medium.
7
In efforts to improve efficacy and/or reduce the risk of increasing antibiotic resistance, researchers are evaluating the immunomodulatory potential of AZM derivatives and other macrolide derivatives with the goal of separating the antibiotic from immunomodulatory properties. As a result, some macrolide derivatives have been shown to retain immunomodulatory properties in models of lung inflammation, inflammatory bowel diseases, arthritis, and skin inflammation. [13] [14] [15] [16] [17] [18] The ability of macrolide derivatives to reduce macrophage-mediated neurotoxicity, however, is unknown. With the increased use of AZM as an immunomodulatory agent for macrophage-mediated neurotoxicity in CNS pathologies, our goal in the present study was to determine whether macrolide derivatives retain neuroprotective properties. Using a semisynthetic approach to target modification of the sugar moieties of AZM, we generated a small library of derivatives, some of which lacked the cladinose found in the parent. We then tested the cytokine profiles and neurotoxicity of M1-stimulated BMDMs treated with derivatives and observed that unique derivatives reduce M1-macrophage activation and subsequent neuron death.
Previously we determined that the effect of BMDMs in vitro is predictive of macrophage responses in the injured CNS 8,19,20 ; therefore, the results of the current study open new therapeutic avenues for the management of maladaptive inflammation in CNS disorders.
| ME THODS

| Semisynthesis of AZM derivatives
Like other macrolides, AZM inhibits bacterial protein synthesis by binding to the 50S subunit of ribosome and thus interfering with the growth of the polypeptide chain. 21, 22 Specifically, the sugar moieties are known to play an essential role in establishing binding interactions with the bacterial ribosomal assembly. We used a semisynthetic approach to create derivatives with targeted alterations in these bacterial binding sugar residues. The AZM derivatives that were synthesized and structurally confirmed by spectroscopic analysis are listed in Table 1 . See Supporting information for mass and H NMR spectrum profiles.
AZM 1: The removal of the cladinose of AZM followed a previously described procedure. 23 Briefly, AZM (6.67 mmol) was dissolved into 
| Antibiotic activity
The minimum inhibitory concentration (MIC) displays the relative antibiotic potency of AZM and each derivative against a common strain of bacteria (Staphylococcus aureus). The protocol used for the determination of the MIC was as previously described with minor modifications. 24 Staphylococcus aureus subsp aureus Rosenbach Table 1 . TA B L E 1 (Continued)
| Preparation of bone marrow-derived macrophages (BMDMs) and macrophage-conditioned medium (MCM)
BMDMs were isolated from the femurs and tibias of C57BL/6 mice 
| Statistical analyses
Results are expressed as mean ± standard deviation (SD) and analyzed using GraphPad Prism 6.0 (GraphPad Software). Data were compared by one-way analysis of variance (ANOVA) among groups followed by F I G U R E 1 Altering the antibiotic properties of azithromycin does not decrease macrophage viability. Bone marrow-derived macrophages (BMDMs) were isolated from adult mice and were treated with AZM, AZM1, AZM4, AZM5, and AZM7 at concentrations of 1, 5, 25, and 125 μmol/L for 24 h Cell viability was measured by using MTT assay. AZM or AZM derivatives exhibited no cytotoxicity at any tested concentration as compared to unstimulated, nontreated BMDM control (dotted line). Moreover, AZM and AZM derivatives at 25 and/or 125 μmol/L significantly increased proliferation of BMDMs as compared to unstimulated controls at *P < 0.05, **P < 0.01, ***P < 0.001. Data are mean ±SD and representative of three independent biological replicate experiments Dunnett's or Holmes-Sidak multiple comparison tests. Differences were determined to be statistically significant at P value ≤0.05.
| RE SULTS
| Assessment of macrophage viability
We chose to use primary bone marrow-derived macrophages (BMDMs)
for our studies as BMDM responses in vitro are predictive of CNS macrophage response in vivo. When stimulated with LPS+IFN-gamma),
BMDMs model proinflammatory macrophages found in neuropathologies. 2, 8, 19 No doses of AZM or its derivatives were toxic to BMDMs when applied directly to the cells for 24 hours (Figure 1 ). Interestingly, this prolonged stimulation of BMDMs with high doses of AZM and its derivatives resulted in increased readouts on the MTT assay indicative of increased BMDM proliferation or increased metabolic activity (Figure 1 ).
This effect was not as robust after 6 hours of stimulation ( Figure S8 ), and therefore, a 6-hr stimulation time point was used for subsequent assays. 
| Macrophage-mediated neurotoxicity with derivatives
We previously reported that M1 supernatant, that is, macrophageconditioned medium (MCM), is neurotoxic when applied to neuron cells and treatment of M1 macrophages with AZM significantly alleviates this neurotoxic effect. Figure 3 ). Direct application of AZM on N2A cells had no effect on cell viability, and MCM isolated from BMDMs treated with AZM in the absence of M1 stimulants had no effect on neuron viability (Figure 3 ).
AZM5 was the most comparable to AZM in alleviating neurotoxicity of M1-stimulated BMDMs, with concentrations of 25 and
Nonantibiotic macrolides decrease the neurotoxic potential of proinflammatory macrophages. Neuron 2A (N2A) cells were incubated with MCM for 24 h MCM from M1 macrophages reduced neuron cell viability significantly as compared to control (N2a cells treated with MCM from unstimulated, nontreated BMDMs, dotted line), M1 vs Control at $$$$P < 0.0001). MCM from M1 macrophages coincubated with AZM and/or AZM 4, AZM 5, and AZM 7 at 25 and/or 125 μmol/L restored neuron cell viability as compared to M1 MCM (*P < 0.05, P < 0.01, P < 0.0001 vs M1). Derivative AZM 1 exhibited no effect in modulating M1 MCM-induced neurotoxicity. Data are mean ± SD and representative of three independent biological replicate experiments 125 μmol/L both showing significant neuroprotective effects (P < 0.01 and P < 0.0001, respectively, vs M1). Derivatives AZM4
and AZM7 at the concentration of 125 μmol/L also significantly attenuated the neurotoxic effect of M1 MCM (P < 0.0001 vs M1).
Contrastingly, AZM1 did not significantly decrease M1 MCM-induced neurotoxicity at any tested concentrations.
| D ISCUSS I ON
In this study, we demonstrate the retention of immunomodulatory activity in AZM derivatives with altered sugar moieties using ourin vitro model of macrophage CNS inflammation. This model accurately predicts the macrophage/microglial response in the injured CNS. Collectively, we demonstrate that AZM derivatives with altered sugar moieties retain immunomodulatory properties. We did not, however, observe uniform immunomodulatory and neu-
roprotective properties with all derivatives tested. AZM7, which had the most extensive chemical modifications (diacetylation and the removal of the cladinose moiety), invoked modest immunomodulatory effects exclusively at the highest concentration tested. Interestingly, however, AZM7 did not retain any antistaphylococcal activity. Similarly, AZM4, which also lacks the cladinose that is replaced by a carbonyl, had modest yet significant immunomodulatory effects with minimal antistaphylococcal activity.
Although AZM1 at the concentration of 125 μmol/L significantly increases IL-10 level, it has no effect in reducing IL-12 production.
Interestingly, AZM1 also induced significant but small changes, relative to AZM, in BMDM metabolic activity at this high dose. While this is clearly important, the molecular target upstream of the NF-κB cascade on which these drugs act remains unclear. 36 In vitro studies show that AZM accumulates in macrophage lysosomes, where it increases the pH, interacts with membrane lipids, induces phospholipidosis, and alters vesicular trafficking which may affect endocytosis and phagocytosis. 37, 38 Other suggested mechanisms indicate that AZM may alter cellular autophagy, or alter the TLR4 signaling pathways by changing endosome trafficking. 37 Further, it remains unknown whether these findings remain valid in vivo or whether derivatives of AZM retain the same mechanism of action. While complicated, continued work in these areas is essential as it could lead to new therapeutics, such as the compounds described here, or provide novel therapeutic targets for future drug development.
One interesting finding in the current study was the fairly pronounced increase in macrophage viability when treated with the highest dose of AZM or derivative for 24 hours (widely used time point for measuring drug toxicity in vitro). This assay measures the conversion of tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to formazan by NAD(P)H-dependent cellular oxidoreductase enzymes, and this measure of metabolic activity is routinely used to quantify changes in cell number or vitality. How AZM and its derivatives induce this effect at high concentrations, and how this may alter inflammatory activities remains unclear, however, it is unlikely that this is directly related to our observed shifts in cytokine profiles and neurotoxicity across drug concentrations. If the observed increases in IL-10 following AZM stimulations were simply a result of cellular proliferation, then IL-12 would also be expected to rise, instead, however, IL-12 levels fell dramatically. Similarly, measurements of cellular proliferation/metabolism at the 6-hour time point, when we measure IL-10/12 levels, displayed more modest increases in proliferation/ metabolism and are thus less likely to influence our cytokine profiles.
In conclusion, we have identified AZM derivatives that retain 
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